A qualitative exploration of the patient disease and treatment burden of end stage renal failure, Post-Renal transplantation and antibody mediated rejection (AMR).

ABSTRACT:

Background

End stage renal disease (ESRD) is the irreversible decline in an individual's kidney function. In severe cases it can be fatal if dialysis or transplantation is not sought. Renal transplantation is associated with longer life expectancies and improved quality of life and is often the preferred treatment over chronic dialysis for those with ESRD. After kidney transplant, patients are at risk of infections, and complications such as allograft rejection. Antibody mediated rejection (AMR) is one of the most common causes of allograft failure. There is currently no approved medication for the prevention or treatment of AMR after transplantation. Whereas the patient-reported symptoms and impacts of ESRD and of kidney transplant have been widely documented, a paucity of these d

SUBMITTER: Barnes N 

PROVIDER: S-EPMC12482816 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature